Read this topic

Clinical Psychopharmacology · Paper A

Lithium interactions and toxicity triggers

The idea

Propranolol treats lithium's tremor — that fact is true and is also the trap. Both drugs independently slow the heart's own pacemaker, so giving them together can produce bradycardia or a drop in blood pressure that has nothing to do with whether the lithium level itself is normal. Treating the tremor correctly does not mean the combination is free of risk.

How it works

Lithium causes a fine, dose-related postural tremor at ordinary therapeutic levels through a direct effect on neuromuscular transmission, and propranolol (a non-selective beta-blocker) reduces this tremor symptomatically by blocking peripheral beta-2-mediated muscle tremor — it does not change the lithium level itself.
Independently of the tremor, both drugs slow cardiac conduction through completely different mechanisms: propranolol blocks beta-1 receptors at the sinoatrial node, directly reducing heart rate, while lithium has its own separate, direct depressant effect on cardiac conduction tissue.
Because the two slowing effects add together (a pharmacodynamic, not pharmacokinetic, interaction), a patient can develop symptomatic bradycardia or hypotension on this combination even when the lithium level itself is checked and found to be within the therapeutic range.
In practice, this means heart rate and blood pressure need their own monitoring when a beta-blocker is started on lithium — a normal lithium level on the same day does not exclude the interaction.
This additive cardiac mechanism is distinct from the pharmacokinetic lithium interactions (ACE inhibitors, ARBs, NSAIDs, thiazide diuretics), which instead reduce renal lithium clearance and raise the lithium level itself over days to weeks.
Lithium toxicity is a separate, more dangerous picture entirely: a coarse, irregular tremor accompanied by nausea, vomiting, diarrhoea, ataxia, dysarthria and confusion, with a raised lithium level — propranolol has no role in treating this, and mistaking it for simple tremor delays urgent management.

How to spot it

A vignette describing a fine, high-frequency, dose-related tremor at a therapeutic lithium level, without systemic symptoms, is describing the correct indication for propranolol, not a warning sign.
A vignette describing new bradycardia or hypotension shortly after starting a beta-blocker on lithium, with a NORMAL lithium level checked at the same time, is describing the additive cardiac interaction — the normal level does not exclude it.
A vignette describing a coarse tremor plus nausea, vomiting, ataxia or confusion, with a RAISED lithium level, is describing toxicity, not simple tremor, and needs urgent assessment rather than propranolol.
A vignette describing a rising lithium level over days to weeks after starting an ACE inhibitor, ARB, NSAID or thiazide diuretic is describing the pharmacokinetic (clearance-reducing) interaction, not the beta-blocker's pharmacodynamic one.
A vignette describing tachycardia, hypertension, hyperthermia and neuromuscular signs (clonus, hyperreflexia) after a new serotonergic drug is describing serotonin syndrome, the cardiovascular opposite of the beta-blocker/lithium picture.

Tell it apart

Beta-blocker/lithium bradycardia interaction vs lithium-induced fine tremor — the tremor is the correct indication for starting propranolol; the bradycardia/hypotension is a separate, additive risk that can appear afterwards even while the tremor itself is well controlled.
Beta-blocker/lithium interaction vs lithium toxicity — toxicity adds a coarse tremor, gastrointestinal upset, ataxia and confusion with a RAISED lithium level, and is never treated with propranolol; the cardiac interaction occurs with a NORMAL lithium level.
Beta-blocker/lithium interaction vs ACE inhibitor/NSAID-lithium interaction — the cardiac interaction is pharmacodynamic and level-independent (bradycardia/hypotension with a normal level); the ACE inhibitor/NSAID interaction is pharmacokinetic and level-dependent (a rising lithium level over days to weeks).
Beta-blocker/lithium interaction vs serotonin syndrome — the cardiovascular direction is opposite: bradycardia and hypotension (beta-blocker/lithium) versus tachycardia, hypertension and hyperthermia (serotonin syndrome).
Beta-blocker/lithium interaction vs hypothyroidism — hypothyroidism is lithium's own separate endocrine side effect, developing over months to years and confirmed on thyroid function tests, and can cause bradycardia even with no beta-blocker on board at all.
Beta-blocker/lithium interaction vs sick sinus syndrome — pre-existing conduction disease predisposes to bradycardia independently of any new drug and should be considered when bradycardia predates the beta-blocker being started.

Watch for

⚠️ Assuming that because propranolol correctly treats lithium's tremor, the overall combination is risk-free — the additive cardiac effect is a separate, real risk that needs its own monitoring.
Checking only the lithium level when bradycardia or hypotension appears on this combination, and missing the diagnosis because the level comes back normal — the mechanism here does not depend on the level at all.
Confusing the fine tremor (correct indication for propranolol) with the coarse tremor of toxicity (propranolol has no role, and toxicity is a medical emergency).
Treating any 'lithium plus another drug' scenario as the same interaction — pharmacokinetic (ACE inhibitor, ARB, NSAID, thiazide: raises the level) and pharmacodynamic (beta-blocker: additive cardiac slowing, level-independent) are mechanistically distinct and need different monitoring.
Forgetting that lithium itself can cause hypothyroidism, which independently produces bradycardia — a slow pulse in a long-term lithium patient is not automatically a beta-blocker interaction.

Use it again

First identify which drug was actually added to lithium: a beta-blocker (cardiac-additive, level-independent), an ACE inhibitor/ARB/NSAID/thiazide (level-raising, pharmacokinetic), or a serotonergic agent (a different syndrome entirely with an opposite cardiovascular direction).
If bradycardia or hypotension is described, check whether the lithium level is normal or raised — normal level plus a recently started beta-blocker points to the additive cardiac interaction; a raised level points to toxicity or a clearance-reducing interaction instead.
If a tremor is described, characterise it as fine (correct indication for propranolol) or coarse-plus-systemic-features (toxicity, needs urgent assessment, not propranolol).
If the cardiovascular change is UP (tachycardia, hypertension, fever) rather than down, redirect away from the beta-blocker/lithium picture entirely and consider serotonin syndrome.
If bradycardia is chronic and slowly progressive with no new drug and no beta-blocker on board, consider lithium-induced hypothyroidism or pre-existing conduction disease before defaulting to a drug interaction.

In detail

Hook

A patient's shaking hands finally settle down on propranolol. Two weeks later she feels dizzy standing up, and her lithium level comes back perfectly normal. The tremor fix worked exactly as intended — and it is the same prescription that quietly caused the dizziness.

Plain definition

Beta-blockers (usually propranolol) are the correct treatment for lithium's fine tremor, but beta-blockers and lithium also independently slow the heart, so combining them can cause bradycardia or low blood pressure through simple addition of two separate effects — a risk that exists whether or not the lithium level itself is normal.

Critical caveat

A normal lithium level does NOT exclude the cardiac interaction. It only excludes toxicity. The bradycardia/hypotension risk from combining a beta-blocker with lithium is a drug-level-independent, pharmacodynamic effect — heart rate and blood pressure need their own separate check.

First principles

Lithium tremor: fine, dose-related, from a direct effect on neuromuscular transmission — treated by propranolol's peripheral beta-2 blockade, without touching the lithium level.
Cardiac slowing: propranolol slows the heart via beta-1 blockade at the sinoatrial node; lithium slows the heart via its own direct effect on cardiac conduction tissue. Two separate mechanisms, added together.
Toxicity: a completely different, level-dependent picture — coarse tremor plus systemic upset, with a raised lithium level.

Structured walk-through

For example, a 68-year-old man on lithium starts propranolol for a fine tremor; two weeks later his pulse is 52 and his blood pressure is 100/60, but his lithium level comes back at 0.6 mmol/L — normal. That combination is the additive cardiac interaction, not toxicity, and the fix is to reassess the beta-blocker dose, not the lithium.

Start by asking what changed and what the lithium level shows. A fine tremor at a normal level, with no other symptoms, is the expected indication for propranolol — treat it as intended. New bradycardia or hypotension after starting or increasing a beta-blocker, with a NORMAL lithium level, is the additive cardiac interaction — manage by reviewing the beta-blocker dose and monitoring heart rate/blood pressure, not by adjusting the lithium. A coarse tremor with gastrointestinal upset, or confusion, alongside a RAISED lithium level, is toxicity — this needs urgent lithium level confirmation and likely admission, and propranolol plays no role. A slowly rising lithium level over days to weeks after starting an ACE inhibitor, ARB, NSAID or thiazide diuretic is the separate renal--reducing interaction.

Look-alikes table

Presentation	Likely cause	Key separator
Fine tremor, normal level	Lithium-induced tremor	No systemic features; propranolol is correct treatment
Bradycardia/hypotension, normal level, recent beta-blocker start	Beta-blocker/lithium cardiac interaction	Level is normal; mechanism is additive, not level-dependent
Coarse tremor + vomiting//confusion, raised level	Lithium toxicity	Level is raised; medical emergency, no propranolol
Rising level over days-weeks, new ACE inhibitor/ARB/NSAID/thiazide	Reduced renal lithium	Level rises gradually; mechanism is pharmacokinetic
Tachycardia, hypertension, fever, , new drug		Cardiovascular direction is UP, not down

Diagnosis

Diagnosis rests on the combination of the current lithium level, the timing relative to any newly started or changed interacting drug, and the direction and character of the cardiovascular or neurological change described — supported by (for bradycardia), thyroid function tests (to exclude lithium-induced hypothyroidism as an alternative cause of bradycardia), and renal function (relevant to -based interactions).

Management

For the correct tremor indication, continue propranolol at the lowest effective dose per Maudsley Prescribing Guidelines advice, with baseline and follow-up heart rate and blood pressure monitoring. For the additive cardiac interaction, review and, if needed, reduce or stop the beta-blocker, alongside routine lithium monitoring. For lithium toxicity, follow local/NICE-aligned emergency management (urgent level, IV fluids, consider dialysis in severe cases) — propranolol has no role. For a rising level from a clearance-reducing interaction, review the causative drug and adjust the lithium dose against level monitoring.

Exam pearl

When a vignette gives you bradycardia or hypotension on lithium plus a beta-blocker, check what the LEVEL shows before naming toxicity — a normal level points to the additive cardiac interaction, which is level-independent and just as real a diagnosis.

In one line

Propranolol correctly treats lithium's tremor, and the same combination can independently slow the heart through addition of two separate mechanisms — a normal lithium level does not mean the combination is safe.